HBK Investments’s Pacira BioSciences PCRX Stock Holding History

HBK Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,600	Closed	-$365K	–	930
2019 Q1	$365K	Sell	9,600 -3,863	-29%	-$151K	﹤0.01%	893
2018 Q4	$579K	Buy	+13,463	New	+$628K	0.01%	856
2017 Q4	–	Sell	-8,600	Closed	-$323K	–	1089
2017 Q3	$323K	Buy	8,600 +4,400	+105%	+$177K	﹤0.01%	874
2017 Q2	$200K	Buy	+4,200	New	+$195K	﹤0.01%	884
2015 Q1	–	Sell	-2,300	Closed	-$204K	–	1120
2014 Q4	$204K	Buy	+2,300	New	+$218K	﹤0.01%	919

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HBK Investments's PCRX Position: Q2 2019 in Review

HBK Investments sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 9,600 shares — an estimated $365K sold.

HBK Investments first reported a position in PCRX in Q4 2014 and held it in 5 quarters. The position peaked at $579K in Q4 2018. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

HBK Investments reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 9,600 Pacira BioSciences shares in Q2 2019, an estimated $365K.
HBK Investments first reported a position in Pacira BioSciences in Q4 2014 and held it in 5 quarters.
HBK Investments's Pacira BioSciences position peaked at $579K in Q4 2018.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.